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Investigators consistently report fetal toxicity with maternal exposure to ACE inhibitors, including oligohydramnios, renal tubular dysplasia, intrauterine growth restriction (IUGR), delayed development of the calvarium (skull hypoplasia), patent ductus arteriosus, and oligohydramnios-related pulmonary hypoplasia and limb deformities. 2 Ideally, women taking ACE inhibitors are changed to another agent before conception. Because approximately 50% of pregnancies are unplanned 3 and there is an everexpanding list of ACE inhibitors for physicians to identify, the obstetrical provider must be prepared to give accurate information and counseling to women exposed to ACE inhibitors while pregnant. We report the case of a woman with a favorable neonatal outcome after prolonged exposure to an ACE inhibitor during pregnancy.
CASE
A 24-year-old gravid 3, para 1-0-1-1 with a history of peripartum cardiomyopathy was referred to our institution at 24 2/7 weeks' gestation for evaluation and treatment. Her medical history included chronic hypertension for 8 years. Eight months before referral, the patient had had a preterm vaginal delivery of a 22-week previable infant.
One month after the preterm delivery, she presented to her local hospital with a 10-day history of shortness of breath, orthopnea, chest tightness, and palpitations. She was diagnosed with congestive heart failure, renal insufficiency, and nonsustained ventricular tachycardia. Maternal echocardiogram confirmed severe global hypocontractility with a left ventricular ejection fraction of 15%. The remainder of the evaluation was consistent with peripartum cardiomyopathy. She was discharged to home in stable condition on furosemide, carvedilol, amiodarone, nitroglycerin, and amlodipine.
Three months later, a pregnancy was diagnosed at 5 weeks' gestation. She was lost to follow-up until she was referred to our institution at 24 2/7 weeks' gestation. Fetal sonography was performed and showed severe oligohydramnios (amniotic fluid index less than 2), a misshapen cranium with overlapping sutures (Figure 1 ), pericardial effusion, small bladder, echogenic focus in the heart and echogenic bowel. The presence of two normalappearing kidneys was noted and the bladder appeared small. The patient was counseled regarding the findings and the likelihood of a poor prognosis for the infant. Various strategies for the management of the remainder of the pregnancy were discussed, including pregnancy termination, which was declined. The patient was then admitted to the hospital for further evaluation. She was asymptomatic (New York Heart Association Class 1). Medications included carvedilol, amiodarone, benazepril, and furosamide. Maternal echocardiogram showed mild left ventricular dysfunction with left ventricular ejection fraction of 50%. A 24-hour urine showed 900 mg protein/24 hours and creatinine clearance of 140 mg/dl. Benazepril, amiodarone, and lasix were discontinued, and she was discharged to home on carvedilol.
Repeat fetal sonography 18 days later revealed normal amniotic fluid volume, normal cranial anatomy with no skull deformity Maternal exposure to angiotensin -converting enzyme ( ACE ) inhibitors has consistently been associated with significant fetal toxicity. We report the case of a 24 -year -old woman, gravida 3, para 1 -0 -1 -1 who presented at 24 2 / 7 weeks' gestation with initial abnormal fetal sonographic findings, including severe oligohydramnios, misshapen cranium, pericardial effusion, small bladder, and echogenic bowel, all after prolonged exposure to multiple medications including an ACE inhibitor. Eighteen days after discontinuation of the ACE inhibitor, repeat fetal sonography revealed normal amniotic fluid and normal cranial and fetal anatomy. The patient gave birth to a normal infant at 36 weeks' gestation. Poor neonatal outcome with prolonged antenatal exposure to ACE inhibitors is not inevitable. Early follow up sonographic evaluation in patients with prolonged exposure to ACE inhibitors may allow physicians to more accurately counsel patients on pregnancy outcome. Journal of Perinatology (2002) 22, 582 -584 doi:10.1038/sj.jp.7210766
, appropriate interval growth, and a small pericardial effusion. Fetal echocardiogram showed possible coarctation of the aorta. Further prenatal care was remarkable for threatened preterm labor, hypertension requiring the addition of nifedipine, and borderline IUGR with fetal growth at the 5% to 15% on serial sonography. Weekly antenatal fetal testing from 32 weeks' gestation remained reassuring, and umbilical artery Doppler velocimetry performed at 34 weeks' gestation was slightly elevated with an average S/D ratio of 3.1. She was admitted for induction of labor at 36 6/7 weeks' gestation secondary to worsening hypertension and had a spontaneous vaginal delivery of a 2060-g female ( <3rd percentile) with Apgar scores of 7 and 9 at 1 and 5 minutes, respectively. The infant was evaluated by pediatrics and pediatric cardiology. The newborn's initial physical exam was normal. Secondary to bilious vomiting on day 1, an upper GI series was performed and showed no evidence of malrotation. The infant's symptoms resolved by day 2. The infant's serum creatinine on days 1 and 2 were 1.1 and 0.9 mg/dl, respectively. Fetal echocardiogram was normal, with no evident coarctation of the aorta. Mother and infant were discharged to home in good condition with close followup planned. At 1 year of age the infant is healthy and weighs 18 lbs (5th percentile). Maternal echocardiogram performed one-year postpartum revealed an LVEF of 40%.
COMMENT
The adverse effects on the fetus of antenatal exposure to ACE inhibitors are well known. Thus, a consistent recommendation is made to avoid these medications during pregnancy. Pryde et al. 4 in 1993 coined the term ''ACE inhibitor fetopathy,'' characterized by fetal hypotension, anuria-oligohydramnios, growth restriction, pulmonary hypoplasia, renal tubular dysplasia, and hypocalvaria. In a l993 report and a recent editorial, 5 he stated, ''there is no justification for ACE inhibitors use once pregnancy has been documented.'' Barr 2 in a teratogen update on ACE inhibitors described the features and etiologies of the various adverse effects of these medications on the fetus. He concluded that the adverse fetal effects are truly drug related, are not a manifestation of the maternal disease and have plausible biologic explanations. He also noted that there was no convincing information that ACE inhibitors are harmful in the first trimester. Additional work suggests that ACE inhibitors are most likely not a teratogen, but rather a fetotoxic medication. Lip et al. 6 in 1997 reported on 19 of 405 pregnancies exposed to ACE inhibitors during pregnancy. The ACE inhibitor was stopped either before or at the first antenatal visit. Of the 17 pregnancies (two miscarriages) exposed to first-trimester ACE inhibitors and proceeding to deliver in the third trimester, no congenital abnormalities were noted. In a review of the literature and a prospective report of 20 pregnancies, Burrows and Burrows 7 found no evidence that ACE inhibitors are teratogens or abortifacients. Although the sample size of first-trimester exposure is small, Burrows and Burrows 7 felt it was ''unreasonable to create anxiety in the women'' found to be pregnant while on an ACE inhibitor.
In the case report described here and a similar case report by Chisholm et al., 8 reversible severe oligohydramnios and delivery of healthy infants were reported in pregnancies complicated by prolonged fetal exposure to ACE inhibitors. The patients required hospitalization with follow-up sonography at 18 days in this patient and 12 days in the case described by Chisholm revealing a normal amount of amniotic fluid. These two case reports give evidence that the fetotoxic effects of ACE inhibitors may, in some cases, be reversible. In the case report described here, an adjustment had to be made concerning counseling on the perceived pregnancy outcome. The patient then gave birth to a normal infant at 36 weeks' gestation.
The number of ACE inhibitors has expanded since their introduction for the treatment of hypertension. In addition, ACE inhibitors have been added to other classes of medications, such as diuretics and calcium channel blockers. A recent review (April 2002) in PDR.NET revealed 24 Trade Name medications containing ACE inhibitors (Table 1) . 9 This may result in confusion regarding medication classification, making it imperative for physicians to thoroughly review a patient's medication list using resource manuals, especially those patients with reproductive potential.
The current evidence of adverse fetal effects from exposure to ACE inhibitors supports the recommendation of discontinuation of ACE inhibitors and the use of an alternative medication before pregnancy, or as soon as pregnancy is documented. As this case report demonstrates, however, poor neonatal outcome after prolonged antenatal exposure to ACE inhibitors is not inevitable. The prolonged exposure to an ACE inhibitor and the abnormal sonographic findings led the obstetrical team to predict a poor perinatal outcome, a prediction that later was proved to be incorrect. The fetal effects of long-term antenatal exposure to ACE inhibitors may be reversible and these patients must be made aware of this. Follow up sonography provides important information that allows physicians to more accurately predict the outcome of these pregnancies.
